Alimera Sciences, Inc. (Alimera), a global pharmaceutical company, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has received approval, including a positive determination for the pricing and reimbursement, for Iluvien for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye from the Italian Medicines Agency, AIFA.
